Open AccessEfficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease
Author(s) -
Nancy A. Rigotti,
Andrew Pipe,
Neal L. Benowitz,
Carmen Arteaga,
Dahlia Garza,
Serena Tonstad
Publication year - 2010
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.109.869008
Subject(s) - medicine , varenicline , smoking cessation , disease , intensive care medicine , pathology
Smoking cessation is a key component of secondary cardiovascular disease prevention. Varenicline, a partial alpha4beta2 nicotinic acetylcholine receptor agonist, is effective for smoking cessation in healthy smokers, but its efficacy and safety in smokers with cardiovascular disease are unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom